Treatment of Chronic Parkinson's Disease with Controlled-Release Carbidopa/Levodopa Academic Article Article uri icon


MeSH Major

  • Breast Implants
  • Mammaplasty
  • Surgical Flaps


  • Controlled-release carbidopa/levodopa 50/200 (SINEMET CR) and standard carbidopa/levodopa (SINEMET 25/100) were compared in a double-blind, six-month, crossover study involving 21 patients with chronic Parkinson's disease and motor response fluctuations. Daily dosage frequency was significantly reduced with SINEMET CR compared with SINEMET 25/100, while the daily amount of levodopa required with SINEMET CR was significantly greater. No significant differences in disability ratings, motor response fluctuations, or safety were detected during double-blind conditions. In the open-label, dose-finding phase of the study, SINEMET CR was superior to standard SINEMET 25/100 in patient ratings of percent "on" time (good motor function), clinical assessments of motor function, and activities of daily living. This finding resulted from a depreciation of the value of the "old drug" rather than an overestimation of the value of the experimental drug. This double-blind study also suggested that elderly male patients with Parkinson's disease derived the greatest benefit from SINEMET CR.

publication date

  • January 1988



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1001/archneur.1988.00520320047014

PubMed ID

  • 3395259

Additional Document Info

start page

  • 861

end page

  • 4


  • 45


  • 8